These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 29265344)

  • 1. Pharmacogenetics of KCNQ channel activation in 2 potassium channelopathy mouse models of epilepsy.
    Vanhoof-Villalba SL; Gautier NM; Mishra V; Glasscock E
    Epilepsia; 2018 Feb; 59(2):358-368. PubMed ID: 29265344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional and behavioral signatures of Kv7 activator drug subtypes.
    Kanyo R; Wang CK; Locskai LF; Li J; Allison WT; Kurata HT
    Epilepsia; 2020 Aug; 61(8):1678-1690. PubMed ID: 32652600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
    Gunthorpe MJ; Large CH; Sankar R
    Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
    Schenzer A; Friedrich T; Pusch M; Saftig P; Jentsch TJ; Grötzinger J; Schwake M
    J Neurosci; 2005 May; 25(20):5051-60. PubMed ID: 15901787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence determinants of subtype-specific actions of KCNQ channel openers.
    Wang AW; Yang R; Kurata HT
    J Physiol; 2017 Feb; 595(3):663-676. PubMed ID: 27506413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 4,5-bisphosphate alters pharmacological selectivity for epilepsy-causing KCNQ potassium channels.
    Zhou P; Yu H; Gu M; Nan FJ; Gao Z; Li M
    Proc Natl Acad Sci U S A; 2013 May; 110(21):8726-31. PubMed ID: 23650395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
    Tatulian L; Delmas P; Abogadie FC; Brown DA
    J Neurosci; 2001 Aug; 21(15):5535-45. PubMed ID: 11466425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
    Main MJ; Cryan JE; Dupere JR; Cox B; Clare JJ; Burbidge SA
    Mol Pharmacol; 2000 Aug; 58(2):253-62. PubMed ID: 10908292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The KCNQ2/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site.
    Padilla K; Wickenden AD; Gerlach AC; McCormack K
    Neurosci Lett; 2009 Nov; 465(2):138-42. PubMed ID: 19733209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scn2a deletion improves survival and brain-heart dynamics in the Kcna1-null mouse model of sudden unexpected death in epilepsy (SUDEP).
    Mishra V; Karumuri BK; Gautier NM; Liu R; Hutson TN; Vanhoof-Villalba SL; Vlachos I; Iasemidis L; Glasscock E
    Hum Mol Genet; 2017 Jun; 26(11):2091-2103. PubMed ID: 28334922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent KCNQ2/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus.
    Kalappa BI; Soh H; Duignan KM; Furuya T; Edwards S; Tzingounis AV; Tzounopoulos T
    J Neurosci; 2015 Jun; 35(23):8829-42. PubMed ID: 26063916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs.
    Miceli F; Soldovieri MV; Martire M; Taglialatela M
    Curr Opin Pharmacol; 2008 Feb; 8(1):65-74. PubMed ID: 18061539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuron-specific Kv1.1 deficiency is sufficient to cause epilepsy, premature death, and cardiorespiratory dysregulation.
    Trosclair K; Dhaibar HA; Gautier NM; Mishra V; Glasscock E
    Neurobiol Dis; 2020 Apr; 137():104759. PubMed ID: 31978607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Kv1.1 null mouse, a model of sudden unexpected death in epilepsy (SUDEP).
    Moore BM; Jerry Jou C; Tatalovic M; Kaufman ES; Kline DD; Kunze DL
    Epilepsia; 2014 Nov; 55(11):1808-16. PubMed ID: 25377007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kv1.1 potassium channel deficiency reveals brain-driven cardiac dysfunction as a candidate mechanism for sudden unexplained death in epilepsy.
    Glasscock E; Yoo JW; Chen TT; Klassen TL; Noebels JL
    J Neurosci; 2010 Apr; 30(15):5167-75. PubMed ID: 20392939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic potential of neuronal KCNQ channel modulators.
    Gribkoff VK
    Expert Opin Ther Targets; 2003 Dec; 7(6):737-48. PubMed ID: 14640909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drosophila KCNQ channel displays evolutionarily conserved electrophysiology and pharmacology with mammalian KCNQ channels.
    Cavaliere S; Hodge JJ
    PLoS One; 2011; 6(9):e23898. PubMed ID: 21915266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation.
    Dost R; Rostock A; Rundfeldt C
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):382-90. PubMed ID: 15007538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retigabine, a Kv7.2/Kv7.3-Channel Opener, Attenuates Drug-Induced Seizures in Knock-In Mice Harboring Kcnq2 Mutations.
    Ihara Y; Tomonoh Y; Deshimaru M; Zhang B; Uchida T; Ishii A; Hirose S
    PLoS One; 2016; 11(2):e0150095. PubMed ID: 26910900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. KCNQ3 is the principal target of retigabine in CA1 and subicular excitatory neurons.
    Varghese N; Lauritano A; Taglialatela M; Tzingounis AV
    J Neurophysiol; 2021 Apr; 125(4):1440-1449. PubMed ID: 33729829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.